A combination can leave measured drug exposure largely unchanged while producing different physiological responses. A 2013 lisdexamfetamine–venlafaxine study illustrates why a finding of pharmacokinetic equivalence should not be shortened to “no interaction.”
What combination was studied?
Ermer and colleagues enrolled 80 healthy adults aged 18–45; 77 entered the pharmacokinetic and safety analyses. This was an open-label investigation with randomization to two treatment sequences. Each sequence began with one drug alone, followed by coadministration.
Oral lisdexamfetamine dimesylate was titrated through 30, 50 and 70 mg/day, while venlafaxine extended-release was titrated through 75, 150 and 225 mg/day. Each step lasted five days. Combination treatment occupied days 16–30, with final daily doses of 70 mg lisdexamfetamine and 225 mg venlafaxine extended-release. These describe the historical protocol, not a dosing recommendation.
What did the plasma measurements show?
The investigators measured the prodrug, active d-amphetamine, venlafaxine and O-desmethylvenlafaxine. In Table 3, combination-to-alone ratios for d-amphetamine were 0.967 for peak concentration, with a 90% confidence interval of 0.821–1.139, and 0.95 for exposure over the sampled dosing interval, with an interval of 0.806–1.121. Both met the prespecified 0.80–1.25 bioequivalence criterion.
Venlafaxine exposure increased and its metabolite exposure decreased in the comparison, while their combined measure met the equivalence criterion. A statement about the combined analytes should therefore not be substituted for a statement that neither component changed.
Did cardiovascular observations remain the same?
No. The largest mean pulse increases were approximately 9–13 beats/minute during single-drug treatment and 18–21 during combination treatment across the two sequences. Maximum mean systolic-pressure increases were approximately 4–7 mmHg alone and 13–14 mmHg combined.
These are maxima of group mean changes under a scheduled observation protocol. They are not individual patient ranges, a frequency of adverse reactions, or estimates of long-term cardiovascular events. The study reported no discontinuation because of a vital-sign increase.
Why does equivalence not settle the physiological question?
A concentration–time comparison describes pharmacokinetics. Pulse and pressure are separate outcomes. Similar active-amphetamine exposure does not logically require identical responses when a second active medicine is present.
The equivalence test also applies to specified endpoints and confidence limits. It does not prove identical concentrations at every moment, identical effects in every participant, or absence of every possible interaction. Extending it to those claims changes the question the experiment answered.
How should the serious event be placed in the timeline?
One participant experienced presyncope during day-five lisdexamfetamine titration at 30 mg/day and discontinued. That occurred before combination treatment. Assigning the event to coadministration merely because it appeared in a combination-study report would misstate its chronology.
What limits clinical or forensic interpretation?
The sample consisted mainly of healthy white men, and exposure was short term. Treatment proceeded from a single drug to the combination within each sequence. The experiment did not establish long-term safety in people with psychiatric or medical comorbidity, and it did not measure driving impairment.
A faithful conclusion preserves both findings: active-amphetamine exposure met the study’s equivalence rule, and observed vital-sign changes were larger during coadministration. Neither finding should erase the other or become an individual causal opinion without the person’s actual clinical and exposure record.
Source
Ermer J and colleagues. Lisdexamfetamine dimesylate and venlafaxine extended-release pharmacokinetics, alone and combined, in healthy adults. Clinical Drug Investigation. 2013;33(4):243–254. DOI: 10.1007/s40261-013-0073-1. Full article and complete title; bibliographic record.